Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.82 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171429 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL17117812 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL18785118 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL48232 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL1971161 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL2231785 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| Water SCHEMBL7247857 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL29258727 | 0.96 | POLB (0.77) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL30927571 | 0.96 | POLB (0.77) | POLBP2RY2P2RY4P2RY6NT5E | |
| Triphosphate SCHEMBL27909453 | 0.96 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| EP-3612181-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme Inc (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195450-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180064811-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-08 | — | — | US | disclosed |
| EP-3066125-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS | Boehringer Ingelheim International GmbH (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067570-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150125447-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | POLB 893/4885P2RY2 4349/4885P2RY4 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.